...
首页> 外文期刊>Oncology letters >Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1
【24h】

Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1

机译:MicroRNA-128在骨肉瘤瘤瘤瘤肿瘤瘤肿瘤瘤肿瘤的调节机制,通过靶向SASH1

获取原文
获取原文并翻译 | 示例

摘要

Osteosarcoma, which commonly occurs in young individuals, is a type of malignant tumor of growing bones. MicroRNAs (miRNAs) have been found to be involved in various cancer-related processes. In the present study, it was reported that miRNA-128 (miR-128) was overexpressed in pathological tissues from patients with osteosarcoma. The present study investigated the possible regulatory mechanism of miR-128 on the progression of osteosarcoma and offered a foundation for clinical therapeutics in osteosarcoma. First, the expressions levels of miR-128 and its target gene, SAM and SH3 domain-containing 1 (SASH1), were measured in tissues from patients with osteosarcoma, and their correlation with osteosarcoma in terms of the pathological level were examined. The effects of miR-128 on osteosarcoma cell proliferation and apoptosis were examined, and its regulation of the expression levels of SASH1 and associated proteins was analyzed. Subsequently, the association between SASH1 and miR-128 was evaluated using a dual luciferase gene reporter assay. Finally, an in vivo xenograft tumor mouse model of osteosarcoma was established to confirm the in vitro results. The results demonstrated a higher expression of miR-128 in pathological tissues, compared with that in normal tissues. From examining the patient osteosarcoma tissues, marked correlations were found between the expression of miR-128 and that of SASH1, particularly with tumor size, invasion depth, lymph node metastasis, and tumor-node-metastasis stage. Compared with the negative control group and blank control group, the results showed that the inhibition of miR-128 led to a lower cell proliferation rate and higher apoptotic rate in MG-63 cells (P0.05). Additionally, the expression of B-cell lymphoma 2 (Bcl-2) was downregulated in the miR-128-inhibited group, compared with that in the control group, whereas the expression levels of SASH1, Bcl-2-associated X protein and caspase-3 were upregulated in the group with miR-128 inhibition (P0.05). SASH1 was confirmed as a direct target of miR-128 using a dual luciferase gene reporter assay. Finally, the downregulation of miR-128 was found to induce tumor suppressive effects on xenograft tumor models of osteosarcoma in mice in vivo. The results of the present study suggested that miR-128 may regulate the tumorigenesis and evolution of osteosarcoma through targeting SASH1.
机译:常常发生在年轻个体中的骨肉瘤是一种生长骨骼的恶性肿瘤。已发现MicroRNAS(miRNA)参与各种癌症相关的过程。在本研究中,据报道,MiRNA-128(miR-128)在患有骨肉瘤患者的病理组织中过表达。本研究研究了MIR-128对骨肉瘤进展的可能调节机制,并为骨肉瘤的临床治疗方法提供了基础。首先,在来自骨肉瘤患者的组织中测量MiR-128及其靶基因,SAM和SH3结构域1(SASH1)的表达水平,并检查其与病理水平方面与骨肉瘤的相关性。研究了MIR-128对骨肉瘤细胞增殖和细胞凋亡的影响,分析了SASH1和相关蛋白表达水平的调节。随后,使用双荧光素酶基因报告器测定评估SASH1和MIR-128之间的关联。最后,建立了骨肉瘤的体内异种移植肿瘤小鼠模型,以确认体外结果。结果表明,与正常组织相比,病理组织中miR-128的表达更高。根据检查患者骨肉瘤组织,在miR-128的表达和sash1的表达之间发现了标记的相关性,特别是肿瘤大小,侵袭深度,淋巴结转移和肿瘤节点转移阶段。与阴性对照组和空白对照组相比,结果表明,MIR-128的抑制导致较低的细胞增殖率和Mg-63细胞中较高的凋亡率(P <0.05)。另外,与对照组的比较,在miR-128抑制基团中下调B细胞淋巴瘤2(Bcl-2)的表达,而SASH1,BCL-2相关X蛋白和胱天蛋白酶的表达水平在具有miR-128抑制的基团中上调-3(P <0.05)。使用双荧光素酶基因报告分析确认SASH1作为miR-128的直接靶标。最后,发现miR-128的下调诱导肿瘤抑制对体内小鼠骨肉瘤的异种移植肿瘤模型诱导肿瘤抑制作用。本研究的结果表明,MiR-128可以通过靶向SASH1调节骨肉瘤的肿瘤发生和演化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号